Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nitric Acid SCHEMBL6033841 | 0.88 | HTT (0.49) | HTTCYP2C19ALDH1A1NPC1RAB9A | |
| Nitric Acid SCHEMBL6033852 | 0.88 | HTT (0.49) | HTTCYP2C19ALDH1A1NPC1RAB9A | |
| SCHEMBL31195423 | 0.85 | HTT (0.46) | HTTCYP2C19ALDH1A1NPC1RAB9A | |
| SCHEMBL4098040 | 0.85 | HTT (0.46) | HTTCYP2C19ALDH1A1NPC1RAB9A | |
| SCHEMBL11880613 | 0.84 | SMN1; SMN2 (0.44) | HTTALDH1A1SMN1; SMN2CA9PKM | |
| Hydrochloric Acid SCHEMBL4476848 | 0.84 | HTT (0.45) | HTTCYP2C19ALDH1A1NPC1RAB9A | |
| SCHEMBL11320624 | 0.83 | RAB9A (0.56) | HTTCYP2C19ALDH1A1NPC1RAB9A | |
| SCHEMBL4491417 | 0.81 | KMT2A (0.48) | — | |
| SCHEMBL10310448 | 0.81 | MAP2K2 (0.43) | HTTCA1CA2CA9LMNA | |
| SCHEMBL11882695 | 0.81 | MAP2K1 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1799684-B1 | LACTAM COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | MILLENNIUM PHARM INC (US) | 2014-12-03 | — | — | EP | disclosed |
| US-20120178739-A1 | LACTAM COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-07-12 | — | — | US | disclosed |
| US-20120178739-A1 | LACTAM COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-07-12 | — | — | US | disclosed |
| US-20110039820-A1 | LACTAM COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-02-17 | — | — | US | disclosed |
| US-20110039820-A1 | LACTAM COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-02-17 | — | — | US | disclosed |
| US-20090105213-A1 | Lactam compounds useful as protein kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-04-23 | — | — | US | disclosed |
| US-20090105213-A1 | Lactam compounds useful as protein kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-04-23 | — | — | US | disclosed |
| US-7459448-B2 | Lactam compounds useful as protein kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-12-02 | — | — | US | disclosed |
| US-7459448-B2 | Lactam compounds useful as protein kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-12-02 | — | — | US | disclosed |
| EP-0532642-A4 | — | — | 1994-04-27 | — | — | EP | disclosed |
| EP-0532642-A1 | SUBSTITUTED GUANIDINES HAVING HIGH BINDING TO THE SIGMA RECEPTOR AND THE USE THEREOF | STATE OF OREGON, acting through OREGON STATE BOARD OF HIGHER EDUCATION, acting for OREGON HEALTH SC. UNIV. AND UNIV. OF OREGON (US) | 1993-03-24 | — | — | EP | disclosed |
| WO-1991018868-A1 | SUBSTITUTED GUANIDINES HAVING HIGH BINDING TO THE SIGMA RECEPTOR AND THE USE THEREOF | STATE OF OREGON, acting by and through the OREGON STATE BOARD OF HIGHER EDUCATION, acting for and onbehalf of the OREGON HEALTH SCIENCES UNIVERSITY (US) | 1991-12-12 | — | — | WO | disclosed |
| US-3976643-A | FROM AN ANILINE AND CYANAMIDE | WILLIAM H. RORER, INC. (US) | 1976-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178739-A1 | LACTAM COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | PRKCI, PIK3CA, AKT1 | HTT 4451/4885CYP2C19 2758/4885ALDH1A1 4635/4885 |
| US-20090105213-A1 | Lactam compounds useful as protein kinase inhibitors | PRKCI, PIK3CA, AKT1 | HTT 4451/4885CYP2C19 2758/4885ALDH1A1 4635/4885 |
| US-20110039820-A1 | LACTAM COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | PRKCI, PIK3CA, AKT1 | HTT 4451/4885CYP2C19 2758/4885ALDH1A1 4635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.